- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04226248
CHIEF PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease) (CHIEF PD)
CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease: A Phase 3 Randomised, Double-blind Placebo-controlled Trial of Rivastigmine to Prevent Falls in Parkinson's Disease.
Parkinson's disease is a common condition particularly affecting older people. Falls are a very frequent complication of the disease affecting 60% of people with Parkinson's every year. As the population ages, the number of people living with Parkinson's disease and the occurrence of complications will increase. The loss of the chemical dopamine in the brain causes walking in Parkinson's to become slower, unsteady and irregular. People with the condition are therefore at a very high risk of falling. To some extent, people can compensate for these changes by paying more attention to their walking. However, Parkinson's also diminishes memory and thinking ability. This decreases people's ability to pay attention to their walking, especially when doing something at the same time.
Cholinesterase inhibitor (ChEis) are drugs that are currently used to treat people with memory problems in Parkinson's. The effect of these drugs on falls in Parkinson's has been tested to show that treatment has the potential to almost halve the number of falls.
This trial aims to definitively determine whether cholinesterase inhibitors (ChEi), can prevent falls in Parkinson's and whether this treatment is cost effective. 600 participants with Parkinson's disease will be enrolled from hospitals throughout the UK. Participants will be randomly assigned to either receive the drug (ChEi) via a patch or receive a placebo (dummy) treatment via a patch.
Neither the researchers nor the participants will know which group they are in. Participants will take the medication for 12 months and record any falls that they experience in diaries. If successful, this treatment in Parkinson's disease, would tackle one of the most disabling complications of the disease and positive findings will provide robust evidence to change clinical practice.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Sandra Neumann, PhD
- Phone Number: 83111 04401174283111
- Email: chief-pd@bristol.ac.uk
Study Contact Backup
- Name: Danielle Pendry-Brazier
- Phone Number: 83113 004401172483113
- Email: chief-pd@bristol.ac.uk
Study Locations
-
-
-
Aberdeen, United Kingdom, AB15 6RE
- Recruiting
- NHS Grampian
-
Contact:
- Julie Scott
- Phone Number: 01224 557948
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Angus Macleod
-
Barnsley, United Kingdom, S75 2EP
- Recruiting
- Barnsley Hospital NHS Foundation Trust
-
Contact:
- Amy Sanderson
- Phone Number: 01226 435084
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Bahaa Madi
-
Bournemouth, United Kingdom, BH23 2JX
- Recruiting
- University Hospitals Dorset NHS Foundation Trust
-
Contact:
- Rochelle Hernandez
- Phone Number: 0300 019 5136
- Email: chief-pd@bristol.ac.uk
-
Contact:
- Emma Gunter
- Phone Number: 0300 019 5284
-
Principal Investigator:
- Divya Tiwali
-
Bridgend, United Kingdom, CF31 1RQ
- Recruiting
- Princess of Wales Hospital (Cwm Taf Morgannwg University Health Board)
-
Contact:
- Deborah Jones
- Phone Number: 01656 752477
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Sandip Raha
-
Bristol, United Kingdom, BS10 5NB
- Recruiting
- North Bristol NHS Trust
-
Contact:
- Catherine Watkins
- Phone Number: 0117 4148276
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Edward Richfield
-
Sub-Investigator:
- Alan Whone
-
Bristol, United Kingdom, BS1 3NU
- Recruiting
- University Hospitals Bristol and Weston NHS Foundation Trust
-
Contact:
- Emma Stratton
- Phone Number: 01174283113
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Emma Stratton
-
Bury, United Kingdom, BL9 7TD
- Recruiting
- Pennine Acute Hospitals NHS Trust
-
Contact:
- Rosan Joseph
- Phone Number: 0161 778 2634
- Email: chief-pd@bristol.ac.uk
-
Contact:
- Sanniah Hussain
- Phone Number: 0161 778 2559
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Jason Raw
-
Derby, United Kingdom, DE22 3NE
- Recruiting
- University Hospitals of Derby and Burton NHS Foundation Trust
-
Contact:
- Melanie Hayman
- Phone Number: 07387248757
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Rob Skelly
-
Dundee, United Kingdom, DD2 1UB
- Recruiting
- NHS Tayside
-
Contact:
- Justine Hudson
-
Principal Investigator:
- Esther Sammler
-
Gateshead, United Kingdom, NE9 6SX
- Recruiting
- Gateshead Health NHS Foundation Trust
-
Contact:
- Bryony Storey
- Phone Number: 01914456317
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Claire McDonald
-
Gloucester, United Kingdom, GL1 3NN
- Recruiting
- Gloucestershire Hospitals NHS Foundation Trust
-
Contact:
- Susan Bullock
- Phone Number: 0300 4225478
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Sangeeta Kulkarni
-
Leeds, United Kingdom, LS2 3AX
- Recruiting
- Leeds Teaching Hospitals NHS Trust
-
Contact:
- Prisca Mpofu
- Phone Number: 01133925073
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Stephen Butterworth
-
Sub-Investigator:
- Jeremy Cosgrove
-
Leicester, United Kingdom, LE1 5WW
- Recruiting
- University Hospitals of Leicester NHS Foundation Trust
-
Contact:
- Jessica Hailstone
- Phone Number: 01162586772
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Kate O'Kelly
-
Liverpool, United Kingdom, L9 7LJ
- Recruiting
- The Walton Centre NHS Foundation Trust
-
Contact:
- Sarah Illingworth
- Phone Number: 0151 556 3963
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Michael Bonello
-
London, United Kingdom, W6 8RF
- Recruiting
- Imperial College Healthcare NHS Trust
-
Contact:
- Raquel Lopes
- Phone Number: 02033111714
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Sophie Molloy
-
London, United Kingdom, WC1N 3BG
- Recruiting
- University College London Hospitals NHS Foundation Trust
-
Contact:
- Angelina Manoharan
- Phone Number: 2034488608
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Tabish Saifee
-
London, United Kingdom, E9 6SR
- Withdrawn
- Homerton University Hospital NHS Foundation Trust
-
Middlesbrough, United Kingdom, TS4 3BS
- Recruiting
- South Tees Hospitals NHS Foundation Trust
-
Contact:
- Marie Branch
- Phone Number: 01642854192
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Louise Wiblin
-
Newcastle, United Kingdom, NE27 0QJ
- Recruiting
- Northumbria Healthcare NHS Foundation Trust
-
Contact:
- Christina Tanney
- Phone Number: 0191 2934087
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- James Fisher
-
Sub-Investigator:
- Richard Walker
-
Newcastle, United Kingdom, NE7 7DN
- Recruiting
- Newcastle Hospitals NHS Foundation Trust
-
Contact:
- Kathryn Walker
- Phone Number: 0191 2081250
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Alison Yarnall
-
Newport, United Kingdom, NP18 3XQ
- Recruiting
- Aneurin Bevan University Health Board
-
Contact:
- Sean Cutler
- Phone Number: 01633 238480
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Alistair Church
-
Oxford, United Kingdom, OX3 9DU
- Recruiting
- Oxford University Hospitals
-
Contact:
- Lauren Whitestone
- Phone Number: 01865 234309
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Sanja Thompson
-
Peterborough, United Kingdom, PE3 9GZ
- Recruiting
- North West Anglia NHS Foundation Trust
-
Contact:
- Natalie Temple
- Phone Number: 01733 673828
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Henry ALDORADIN CABEZA
-
Plymouth, United Kingdom, PL6 5FP
- Recruiting
- University Hospitals Plymouth NHS Trust
-
Contact:
- Marina Dobranszky-oroian
- Phone Number: 01752 437 485
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Camille Carroll
-
Preston, United Kingdom, PR2 9HT
- Recruiting
- Lancashire Teaching Hospitals NHS Foundation Trust
-
Contact:
- Sonia Raj
- Phone Number: 01772 522031
- Email: chief-pd@bristol.ac.uk
-
Reading, United Kingdom, RG1 5AN
- Recruiting
- Royal Berkshire NHS foundation trust
-
Contact:
- Sarosh Khymani
- Phone Number: 1183226608
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Apurba Chatterjee
-
Salford, United Kingdom, MA6 8HD
- Recruiting
- Salford Royal NHS Foundation Trust
-
Contact:
- Jessica Whiston
- Phone Number: 01612060534
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Christopher Kobylecki
-
Stockton-on-Tees, United Kingdom, TS19 8PE
- Recruiting
- North Tees and Hartlepool Hospitals NHS Foundation Trust
-
Contact:
- Elaine Siddle
- Phone Number: 01642 624529
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Arunkumar Annamalai
-
Taunton, United Kingdom, TA1 5DA
- Recruiting
- Somerset NHS Foundation Trust
-
Contact:
- Alison Whitcher
- Phone Number: 01823 343635
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Anita Goff
-
Sub-Investigator:
- Sarah Campbell
-
Wigan, United Kingdom, WN1 2NN
- Recruiting
- Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust
-
Contact:
- Sarah Liderth
- Phone Number: 01942 822014
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Steve Adejumo
-
Wrexham, United Kingdom, LL13 7YP
- Recruiting
- Betsi Cadwaladr University Health Board
-
Contact:
- Claire Watkins
- Phone Number: 03000 858033
- Email: chief-pd@bristol.ac.uk
-
Sub-Investigator:
- Sally Jones
-
Yeovil, United Kingdom
- Recruiting
- Yeovil District Hospital
-
Contact:
- Alison Lewis
- Phone Number: 01935384854
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Rani Sophia
-
-
Accepted
-
Romford, Accepted, United Kingdom, BS8 1NU
- Recruiting
- Barking, Havering and Redbridge University Hospitals NHS Trust
-
Contact:
- Lyn Liddiard
- Phone Number: 01174283113
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Anjum Misbadhuddin
-
-
England
-
Manchester, England, United Kingdom, M13 9WL
- Recruiting
- Manchester University NHS Foundation Trust
-
Contact:
- Sandra Bothwell
- Email: sandra.bothwell@mft.nhs.uk
-
Contact:
- Ailish Fountain
- Email: ailish.fountain@mft.nhs.uk
-
Principal Investigator:
- David Ahearn, MBChB
-
-
Gwynedd
-
Bangor, Gwynedd, United Kingdom, LL57 2PW
- Recruiting
- Betsi Cadwaladr University Health Board
-
Contact:
- Julia Roberts
- Phone Number: 01248 384423
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Sam Abraham
-
-
Norfolk
-
Norwich, Norfolk, United Kingdom, NR4 7UY
- Recruiting
- Norfolk and Norwich University Hospital
-
Contact:
- Alagaratnam Niruban
- Phone Number: 01603 288177
- Email: chief-pd@bristol.ac.uk
-
Principal Investigator:
- Alagaratnam Niruban
-
-
Scotland
-
Edinburgh, Scotland, United Kingdom, EH1 3EG
- Recruiting
- Lothian Health Board NHS
-
Contact:
- Maria Dewar
- Email: maria.dewar@nhslothian.scot.nhs.uk
-
Contact:
- Katie Power
- Email: katie.power@nhslothian.scot.nhs.uk
-
Principal Investigator:
- Gordon Duncan, MBChB
-
Larbert, Scotland, United Kingdom, FK5 4WR
- Recruiting
- NHS Forth Valley
-
Contact:
- David Thomson
- Email: david.thomson@nhs.scot
-
Contact:
- Catherine Pennington
- Email: catherine.pennington@nhs.scot
-
Principal Investigator:
- Catherine Pennington, MBChB
-
-
Somerset
-
Bath, Somerset, United Kingdom, BA1 3NG
- Recruiting
- Royal United Hospitals Bath NHS Foundation Trust
-
Contact:
- Ruth Hamlin
- Phone Number: 01225 825797
- Email: chief-pd@bristol.ac.uk
-
Contact:
- Veronica Lyell
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of idiopathic Parkinson's disease.
- Modified Hoehn and Yahr stage 1-4 disease as determined at baseline visit.
- Have experienced a fall in the previous year.
- Able to walk ≥10m without aids or assistance.
- 18+ years of age.
Exclusion Criteria:
- Previous ChEi use in 12 months prior to enrolment.
- Hypersensitivity to rivastigmine
- Dementia diagnosed according to MDS criteria (6).
- Inability to attend or comply with treatment or follow-up scheduling.
- Non-English-speaking patients (cognitive tests performed in English).
- Falling ≥4x per day.
- Unwillingness to use an acceptable method of contraception for the duration of the trial if they are of childbearing potential.
- Pregnancy and/or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active (Rivastigmine)
Rivastigmine Transdermal Patches
|
Rivastigmine Trandermal Patches applied once a day for up to 12 months
|
Placebo Comparator: Placebo
Placebo Matched Transdermal Patches
|
Placebo Trandermal Patches applied once a day for up to 12 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fall rate
Time Frame: 12 months from the day the IMP is commenced
|
Fall rate measured using monthly diaries and telephone calls prospectively
|
12 months from the day the IMP is commenced
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Parkinson's Disease (PD)
Time Frame: 12 months
|
MDS-UPDRS total score in the practically defined 'ON' state and each individual subscale (1-4)
|
12 months
|
Freezing of gait
Time Frame: 12 months
|
New Freezing of Gait Questionnaire (NFOGQ)
|
12 months
|
Frailty
Time Frame: 12 months
|
Frailty assessed by the SHARE-FI
|
12 months
|
Physical performance
Time Frame: 12 months
|
Measured by the Short physical performance battery (SPPB)
|
12 months
|
Freezing of Gait Assessment
Time Frame: 12 months
|
Gait speed measured with Freezing of Gait (turn test)
|
12 months
|
Gait Assessment
Time Frame: 12 months
|
Gait speed measured with and without dual task
|
12 months
|
Cognition
Time Frame: 12 months
|
Montreal Cognitive Assessment (MoCA)
|
12 months
|
Depression
Time Frame: 12 months
|
Geriatric Depression Scale (GDS)
|
12 months
|
Fear of falling
Time Frame: 12 months
|
Iconographical Fall Efficacy Scale (ICON-FES)
|
12 months
|
Dysphagia
Time Frame: 12 months
|
Swallowing Disturbance Questionnaire (SDQ)
|
12 months
|
Participant health related quality of life
Time Frame: 0,1,3,6 9 and 12 months
|
EuroQoL 5D-5L health status questionnaire (EQ-5D-5L)
|
0,1,3,6 9 and 12 months
|
Capability of older people
Time Frame: 12 months
|
ICEpop CAPability measure for Older people (ICECAP-O)
|
12 months
|
Mortality (all cause and PD-related)
Time Frame: 12 months
|
Office of National Statistics (ONS) data
|
12 months
|
Cost effectiveness by NHS resource use
Time Frame: 12 months
|
NHS Hospital Episode Statistics (HES) data
|
12 months
|
Apathy
Time Frame: 12 months
|
Starkstein Apathy Scale
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Emily Henderson, PhD, University of Bristol
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Parkinson Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Cholinergic Agents
- Enzyme Inhibitors
- Neuroprotective Agents
- Protective Agents
- Cholinesterase Inhibitors
- Rivastigmine
Other Study ID Numbers
- Study 2018-2030
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Rivastigmine Transdermal System
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)Completed
-
NovartisCompletedAlzheimer's DiseaseUnited States
-
University of Maryland, BaltimoreNational Institute on Aging (NIA)CompletedParkinson Disease | Parkinson Disease DementiaUnited States
-
The Cleveland ClinicTerminatedMild Cognitive Impairment | Mild Cognitive DisorderUnited States
-
University of PennsylvaniaCompletedParkinson's Disease | Mild Cognitive ImpairmentUnited States
-
Novartis PharmaceuticalsCompleted
-
NovartisCompletedParkinson's Disease DementiaUnited States, Belgium, Italy, United Kingdom, Germany, Australia, Austria, Spain, Canada, France, Netherlands, Turkey, Argentina
-
UMC UtrechtSt. Antonius Hospital; ZonMw: The Netherlands Organisation for Health Research... and other collaboratorsRecruitingDepressive DisorderNetherlands
-
NovartisCompleted
-
Novartis PharmaceuticalsOno Pharmaceutical Co. LtdCompleted